vimarsana.com
Home
Live Updates
Investigational study provides evidence that recombinant end
Investigational study provides evidence that recombinant end
Investigational study provides evidence that recombinant endolysin XZ 700* is a promising novel non-antibiotic treatment strategy aimed at controlling Staphylococcus aureus S aureus colonization of lesional skin in Cutaneous T-cell lymphoma CTCL
- Research shows XZ.700* could block tumor promoting effects of S. aureus on malignant T cells, potentially delaying tumor progression.
Findings strengthen ...
Related Keywords
Switzerland ,
,
Cutaneoust Cell ,
Investigational ,
Study ,
Rovides ,
Evidence ,
Hat ,
Recombinant ,
Ndolysin ,
00 ,
Romising ,
Novel ,
Son ,
Ntibiotic ,
Treatment ,
Strategy ,
Imed ,
Controlling ,
Staphylococcus ,
Laureus ,
Colonization ,
Esional ,
Skin ,
Cutaneous ,
Fell ,
Lymphoma ,
Tcl ,